Your browser doesn't support javascript.
loading
When Do Women with Second Trimester Pregnancy Loss Need Repeated Doses of Misoprostol? Insights from a Teaching Hospital.
Cohen, Nadav; Cohen, Bracha; Karmakar, Debjyoti; Lavie, Ofer; Zilberlicht, Ariel.
Afiliación
  • Cohen N; Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Cohen B; Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Karmakar D; Pelvic Floor Unit, Western Health, Melbourne, Victoria, Australia.
  • Lavie O; Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Zilberlicht A; Department of Obstetrics and Gynecology, Carmel Medical Center, Haifa, Israel, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Isr Med Assoc J ; 25(12): 799-803, 2023 Dec.
Article en En | MEDLINE | ID: mdl-38142318
ABSTRACT

BACKGROUND:

Cases of second trimester pregnancy loss can be treated either pharmacologically or by surgical evacuation. Misoprostol, an E1-prostaglandin analog, is used to facilitate the evacuation of the uterus.

OBJECTIVES:

To determine the risk factors associated with patients who were treated with five or more repeated doses of misoprostol.

METHODS:

We conducted a retrospective study of patients treated with vaginal misoprostol at our institution between December 2016 and October 2021 for second trimester pregnancy loss.

RESULTS:

In total, 114 patients were eligible for analysis; 83 were treated with < 5 doses and 31 with ≥ 5. We recorded each case in which repeated doses were administered, irrespective of predetermined conditions such as gravidity, parity, maternal age, or gestational age. Moreover, cases of five or more misoprostol dosing were not associated with an increased complications rate, except for the increased duration of hospitalization (3.1 vs. 2.2 days, P-value < 0.01).

CONCLUSIONS:

Repeated dosing could not be predicted before treatment among those treated with vaginally administered misoprostol for second trimester pregnancy loss. However, low complication rates of repeated dosing may reassure both physicians and patients regarding safety, efficacy, and future fertility.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Abortivos no Esteroideos / Misoprostol / Aborto Inducido Límite: Female / Humans / Pregnancy Idioma: En Revista: Isr Med Assoc J / Isr. Med. Assoc. J / Israel Medical Association Journal Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Israel
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Abortivos no Esteroideos / Misoprostol / Aborto Inducido Límite: Female / Humans / Pregnancy Idioma: En Revista: Isr Med Assoc J / Isr. Med. Assoc. J / Israel Medical Association Journal Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Israel Pais de publicación: Israel